These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 25650659)

  • 1. Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression.
    Valenti F; Ganci F; Fontemaggi G; Sacconi A; Strano S; Blandino G; Di Agostino S
    Oncotarget; 2015 Mar; 6(8):5547-66. PubMed ID: 25650659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas.
    Valenti F; Sacconi A; Ganci F; Grasso G; Strano S; Blandino G; Di Agostino S
    Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31514456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair.
    Hartman AR; Ford JM
    Nat Genet; 2002 Sep; 32(1):180-4. PubMed ID: 12195423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
    Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
    BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense inhibition of BRCA1 expression and molecular analysis of hereditary tumors indicate that functional inactivation of the p53 DNA damage response pathway is required for BRCA-associated tumorigenesis.
    Reedy MB; Hang T; Gallion H; Arnold S; Smith SA
    Gynecol Oncol; 2001 Jun; 81(3):441-6. PubMed ID: 11371136
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas.
    Yoshikawa K; Ogawa T; Baer R; Hemmi H; Honda K; Yamauchi A; Inamoto T; Ko K; Yazumi S; Motoda H; Kodama H; Noguchi S; Gazdar AF; Yamaoka Y; Takahashi R
    Int J Cancer; 2000 Oct; 88(1):28-36. PubMed ID: 10962436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repression of new p53 targets revealed by ChIP on chip experiments.
    Ceribelli M; Alcalay M; Viganò MA; Mantovani R
    Cell Cycle; 2006 May; 5(10):1102-10. PubMed ID: 16721047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Repression of BRCA1 through a feedback loop involving p53.
    MacLachlan TK; Dash BC; Dicker DT; El-Deiry WS
    J Biol Chem; 2000 Oct; 275(41):31869-75. PubMed ID: 10884389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. S100A2 is a BRCA1/p63 coregulated tumour suppressor gene with roles in the regulation of mutant p53 stability.
    Buckley NE; D'Costa Z; Kaminska M; Mullan PB
    Cell Death Dis; 2014 Feb; 5(2):e1070. PubMed ID: 24556685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
    Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
    Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors.
    Sourvinos G; Spandidos DA
    Biochem Biophys Res Commun; 1998 Apr; 245(1):75-80. PubMed ID: 9535786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differing effects of breast cancer 1, early onset (BRCA1) and ataxia-telangiectasia mutated (ATM) mutations on cellular responses to ionizing radiation.
    Mamon HJ; Dahlberg W; Azzam EI; Nagasawa H; Muto MG; Little JB
    Int J Radiat Biol; 2003 Oct; 79(10):817-29. PubMed ID: 14630541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.
    Weigman VJ; Chao HH; Shabalin AA; He X; Parker JS; Nordgard SH; Grushko T; Huo D; Nwachukwu C; Nobel A; Kristensen VN; Børresen-Dale AL; Olopade OI; Perou CM
    Breast Cancer Res Treat; 2012 Jun; 133(3):865-80. PubMed ID: 22048815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolin-1 controls BRCA1 gene expression and cellular localization in human breast cancer cells.
    Glait C; Ravid D; Lee SW; Liscovitch M; Werner H
    FEBS Lett; 2006 Oct; 580(22):5268-74. PubMed ID: 16979166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressor p53 is required to modulate BRCA1 expression.
    Arizti P; Fang L; Park I; Yin Y; Solomon E; Ouchi T; Aaronson SA; Lee SW
    Mol Cell Biol; 2000 Oct; 20(20):7450-9. PubMed ID: 11003642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution.
    Greenblatt MS; Chappuis PO; Bond JP; Hamel N; Foulkes WD
    Cancer Res; 2001 May; 61(10):4092-7. PubMed ID: 11358831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro analysis of genomic instability triggered by BRCA1 missense mutations.
    Quaresima B; Faniello MC; Baudi F; Crugliano T; Cuda G; Costanzo F; Venuta S
    Hum Mutat; 2006 Jul; 27(7):715. PubMed ID: 16786532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features.
    Otis CN; Krebs PA; Albuquerque A; Quezado MM; San Juan X; Sobel ME; Merino MJ
    Int J Surg Pathol; 2002 Oct; 10(4):237-45. PubMed ID: 12490973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
    Coaxum SD; Tiedeken J; Garrett-Mayer E; Myers J; Rosenzweig SA; Neskey DM
    Oncotarget; 2017 Apr; 8(14):22991-23007. PubMed ID: 28160562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.